LIXT (Lixte Biotechnology Holdings, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Lixte Biotechnology Holdings, Inc. Common Stock (LIXT) is a publicly traded Healthcare sector company. As of May 21, 2026, LIXT trades at $5.60 with a market cap of $54.60M and a P/E ratio of 0.00. LIXT moved +1.90% today. Year to date, LIXT is +48.15%; over the trailing twelve months it is +327.48%. Its 52-week range spans $0.64 to $6.26. Rallies surfaces LIXT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns LIXT stock?

Rallies tracks hedge fund and 13F ownership for LIXT, including fund holders, share counts, and position changes when data is available.

LIXT Key Metrics

Key financial metrics for LIXT
MetricValue
Price$5.60
Market Cap$54.60M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$6.26
52-Week Low$0.64
Volume0
Avg Volume0
Revenue (TTM)$0
Net Income$-6.01M
Gross Margin0.00%

Latest LIXT News

Recent LIXT Insider Trades

  • Bernards Rene bought 5.53K (~$13.87K) on Oct 3, 2023.
  • van der Baan Bastiaan Jeroen bought 10.00K (~$28.00K) on Oct 3, 2023.
  • Bernards Rene bought 5.53K (~$13.87K) on Oct 3, 2023.

LIXT Analyst Consensus

LIXT analyst coverage data. Average price target: $0.00.

Common questions about LIXT

Who owns LIXT stock?
Rallies tracks hedge fund and 13F ownership for LIXT, including fund holders, share counts, and position changes when data is available.
Does Rallies show 13F holders for LIXT?
Yes. Rallies tracks hedge fund and 13F ownership data for LIXT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is LIXT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LIXT. It does not provide personalized investment advice.
LIXT

LIXT